Chimin(SH:603222) Mei Ri Jing Ji Xin Wen·2025-08-21 10:21Core Viewpoint - Jimin Health (603222.SH) reported a significant decline in revenue and a shift from profit to loss in its 2025 semi-annual report, alongside negative cash flow from operating activities [1][4][8]. Financial Performance - The company achieved revenue of 366.45 million yuan, a year-on-year decrease of 21.30% [4][5]. - The net profit attributable to shareholders was -52.70 million yuan, compared to a profit of 25.44 million yuan in the same period last year, marking a decline of 307.10% [4][5]. - The cash flow from operating activities was approximately -36.10 million yuan, a significant drop from about 41.73 million yuan in the previous year [7][8]. - The weighted average return on net assets decreased by 5.24 percentage points to -3.63% [7]. Stock Performance - Jimin Health's stock price increased by 53.78% from August 13 to August 19, 2025, with a trading volume of 1.51 million shares [1][2]. - On August 20, the stock hit the daily limit, with a turnover rate of 31.31%, significantly higher than the industry average [1][2]. - However, on August 21, the stock price experienced a sharp decline, reaching a near 4% drop [1]. Legal Issues - The company faced legal challenges due to the "He Qinghong stamp forgery incident," which significantly impacted sales, particularly for pre-filled catheter flushing devices and safety injection syringes, leading to a 92.24% decline in domestic sales [8][9]. - The incident involved the former vice president He Qinghong and her team forging company seals and signing agreements with distributors, resulting in 19 lawsuits with a total amount involved of 73.06 million yuan [8][9].